12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status:
Withdrawn
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Irritable Bowel Syndrome with diarrhoea (IBS-D) is a functional gastrointestinal disorder
characterised by chronic or recurrent abdominal pain or discomfort and diarrhoea. The aim of
this trial is the evaluation of the efficacy and safety of oral ibodutant 10 mg once daily as
compared to placebo in women with IBS-D over a 12-week treatment period.